@Remorhaz I hope $TLX will provide some insights into the economics of the acquired business in due course, as the revenues are material compared with $TLX today.

I’m not too concerned for now as more of the value depends on the progress of approvals of the 2 next diagnostic products. And of course clinical development of the therapeutics.

I imagine this could be a very smart move.

$CSL’s Behring business has shown how valuable a vertically integrated model can be when the supply chain is not commoditised. I suspect radiopharmacy - -while of course entirely different - offers the potential for significant benefits from being vertically integrated. Precise control of timing for the last mile is huge in this supply chain!

My triggers to build my position, however, rest on the product portfolio’s progression. And that’s because I can’t quantify just how critical the integrated model is here.